An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: Results of a phase II prospective trial

Abstract

Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-Transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-Transplant ZA from days 100 to 365 post alloSCT was determined by a risk-Adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with ..